Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Guardant Health, Inc. GH

Healthcare  —  Diagnostics & Research
177.25 0.80 0.45% as of 25 Sep
Market cap
$23.9B
P/E
0.0×
Revenue Champion (5y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Guardant Health, Inc. (GH) Business Profile

Updated before January 2025

Company Overview

Guardant Health, Inc. (GH) is a leading precision oncology company that leverages advanced technologies to transform cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company is headquartered in Redwood City, California. Guardant Health’s mission is to conquer cancer with data-driven insights, enabling earlier detection, treatment, and monitoring of the disease. The company is led by a strong executive team, with Helmy Eltoukhy serving as Co-CEO and Chairman, and AmirAli Talasaz as Co-CEO and President. Their leadership has been instrumental in driving innovation and expanding the company’s footprint in the oncology diagnostics market.

Core Business Segments

Guardant Health operates across several core business segments, focusing on liquid biopsy-based diagnostics and data-driven oncology solutions. These segments include:

1. Oncology Testing

  • Guardant360®: A flagship liquid biopsy test that provides comprehensive genomic profiling for advanced cancer patients. It helps oncologists identify actionable mutations and guide targeted therapies.
  • Guardant360 CDx: A companion diagnostic test approved by the FDA, designed to match patients with specific therapies based on their tumor profiles.
  • GuardantOMNI®: A high-definition liquid biopsy test tailored for biopharmaceutical companies conducting clinical trials and drug development.

2. Early Cancer Detection

  • Guardant Reveal™: A test designed for residual disease detection and recurrence monitoring in early-stage cancer patients. It provides insights into minimal residual disease (MRD) using blood samples.
  • Screening Initiatives: Guardant Health is actively developing tests for early cancer detection, including colorectal cancer screening through its Guardant Shield™ program.

3. Biopharma Solutions

  • Clinical Trial Support: Guardant Health partners with pharmaceutical companies to accelerate drug development by providing genomic insights and biomarker discovery.
  • Real-World Evidence: The company offers data analytics services to support clinical decision-making and improve patient outcomes.

4. Data Insights and Analytics

  • GuardantINFORM™: A platform that combines clinical-genomic data to provide actionable insights for healthcare providers, researchers, and biopharma partners.

Business Model

Guardant Health’s business model revolves around integrating cutting-edge technology, data analytics, and clinical expertise to deliver precision oncology solutions. The company generates revenue through:

  • Diagnostic Testing Services: Revenue from liquid biopsy tests like Guardant360, Guardant Reveal, and GuardantOMNI.
  • Biopharma Collaborations: Partnerships with pharmaceutical companies for clinical trials, drug development, and biomarker discovery.
  • Data Licensing: Monetizing clinical-genomic data through platforms like GuardantINFORM.
  • Regulatory Approvals: Expanding the use of FDA-approved tests like Guardant360 CDx to drive adoption and reimbursement.

Guardant Health’s approach emphasizes scalability, leveraging its proprietary technology platform to address diverse oncology needs while maintaining cost efficiency.

Strategic Direction

Guardant Health is committed to advancing precision oncology through innovation and strategic growth. Key focus areas include:

  • Expansion of Early Detection Programs: Scaling up initiatives like Guardant Shield to address the growing demand for non-invasive cancer screening.
  • Global Market Penetration: Expanding its presence in international markets, particularly in regions with high cancer prevalence.
  • R&D Investments: Increasing investment in research and development to enhance test accuracy, broaden test applications, and develop new products.
  • Sustainability Goals: Implementing eco-friendly practices in operations and supply chain management to reduce environmental impact.
  • Strategic Partnerships: Collaborating with healthcare providers, biopharma companies, and research institutions to drive innovation and adoption of its solutions.

Competitive Landscape

Guardant Health operates in a highly competitive market, facing competition from companies specializing in oncology diagnostics, liquid biopsy, and genomic testing. Key competitors include:

  • Foundation Medicine: A leader in comprehensive genomic profiling and companion diagnostics.
  • Exact Sciences: Known for its Cologuard® test for colorectal cancer screening and other diagnostic solutions.
  • Illumina: A pioneer in next-generation sequencing technologies used in cancer research and diagnostics.
  • Natera: Focused on cell-free DNA testing for oncology and reproductive health.
  • Grail, Inc.: Specializes in multi-cancer early detection tests using liquid biopsy technology.

Guardant Health differentiates itself through its proprietary technology, FDA-approved tests, and strong focus on data-driven insights.

Risk Factors

Despite its strong market position, Guardant Health faces several risks, including:

  • Regulatory Challenges: Delays or denials in regulatory approvals for new tests could impact growth.
  • Market Dependence: Reliance on oncology diagnostics and biopharma collaborations makes the company vulnerable to market fluctuations.
  • Supply Chain Disruptions: Dependence on specialized materials and suppliers could lead to operational challenges.
  • Competitive Pressure: Intense competition from established players and new entrants could affect market share.
  • Reimbursement Policies: Changes in insurance coverage and reimbursement rates for diagnostic tests could impact revenue.

Recent Developments

Guardant Health has made significant strides in recent years, including:

  • FDA Approvals: Securing FDA approval for Guardant360 CDx as a companion diagnostic for multiple therapies.
  • Product Launches: Expanding its portfolio with the launch of Guardant Reveal for MRD detection and Guardant Shield for early cancer screening.
  • Strategic Partnerships: Collaborating with leading biopharma companies to accelerate drug development and clinical trials.
  • Global Expansion: Establishing operations in key international markets to drive adoption of its solutions.
  • Technological Advancements: Enhancing its liquid biopsy platform with improved sensitivity and specificity.

Investment Considerations

Investors considering Guardant Health should weigh the following factors:

Strengths

  • Innovative Technology: Proprietary liquid biopsy platform with proven clinical utility.
  • Strong Market Position: Leadership in precision oncology and FDA-approved tests.
  • Growth Potential: Expanding into early cancer detection and global markets.
  • Strategic Partnerships: Collaborations with biopharma companies and healthcare providers.

Risks

  • High Competition: Intense rivalry in the oncology diagnostics market.
  • Regulatory Uncertainty: Dependence on FDA approvals and reimbursement policies.
  • Operational Challenges: Potential supply chain disruptions and scalability issues.

Conclusion

Guardant Health, Inc. is a trailblazer in precision oncology, leveraging innovative technologies to transform cancer care. With a robust portfolio of liquid biopsy tests, strategic partnerships, and a commitment to innovation, the company is well-positioned for long-term growth. However, investors should remain mindful of the competitive landscape and regulatory challenges. As Guardant Health continues to expand its offerings and global reach, it is poised to play a pivotal role in the future of cancer diagnostics and treatment.